OncoMatch/Clinical Trials/NCT06452160
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Is NCT06452160 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies BGC515 for mesothelioma.
Treatment: BGC515 — The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Mesothelioma
Tumor Agnostic
Disease stage
Metastatic disease required
locally advanced or metastatic...at least one measurable lesion
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard-of-care
who have experienced progressive disease or treatment intolerability after receiving the standard-of-care, or refuse to receive or have no access to the standard-of-care
Cannot have received: TEAD inhibitor
Previous or current use of transcriptional enhanced associate domain (TEAD) inhibitors
Lab requirements
Cardiac function
clinically significant cardiovascular disease as defined in the protocol [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06452160 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior TEAD inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages